CD8A and skin cancer: Combinations of antibodies against PD-1, 4-1BB and VISTA fulfil this brief by not only targeting positive and negative signaling pathways on CD8 cytotoxic T cells, but also impacting on CD4 effector T cells, NK cells, regulatory T cells and myeloid-derived suppressor cells within skin cancers (Figure 1).